Randomized, multi-center study of carfilzomib, lenalidomide, and dexamethasone (KRd) with or without daratumumab (D) in patients with newly diagnosed multiple myeloma (NDMM): The ADVANCE clinical trial.

Authors: Carl Ola Landgren, Jing Christine Ye, Jens Hillengass, Douglas W. Sborov, James E. Hoffman, Benjamin Diamond, David Glen Coffey, Marcella Kaddoura, Abhishek Pandey, Kellye Koubek, Stephanie Mompoint, Sindy Gutierrez, Caterine Diaz, Michelle Armogan, Rachid C. Baz, Robert Orlowski, Thomas A. Jandl, Neha Korde, Kenneth H. Shain, Dickran Garo Kazandjian

Published: 2025-05-28

DOI: 10.1200/jco.2025.43.16_suppl.7503

Source: Full article

---

Abstract

7503